Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
Abstract For patients with severe aplastic anemia (SAA) in China who have had an insufficient response to the first-line treatment with hematopoietic stem cell transplantation or immunosuppressive therapy, there is no established standard of care other than transfusion support and treatment of infec...
Main Authors: | Hong Chang, Guangsheng He, Rong Fu, Fei Li, Bing Han, Tao Li, Lei Liu, Hemant Mittal, Hantao Jin, Fengkui Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-45607-0 |
Similar Items
-
PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
by: H. Chang, et al.
Published: (2022-06-01) -
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
by: Zhuxin Zhang, et al.
Published: (2023-09-01) -
The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
by: Ayşe Işık, et al.
Published: (2013-09-01) -
PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
by: Zhuxin Zhang, et al.
Published: (2023-08-01) -
Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
by: Yufei Zhao, et al.
Published: (2023-01-01)